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Warfarin in Dialysis
Patients With
Atrial FibrillationPatients with atrial ﬁbrillation (AF) and end-stage
chronic kidney disease (CKD) receiving dialysis are
at higher risk of stroke (1). Warfarin has been shown
to reduce the frequency of strokes by 64.0% in
patients with AF; however, its use in dialysis patients
has not received consensus owing to the lack of
randomized controlled trial data and associated
increased bleeding risk.
In a recently published paper in the Journal, Bonde
et al. (2) demonstrated that warfarin was associatedwith a reduction in all-cause mortality in high-risk
(CHA2DS2-VASc $2) dialysis patients in a large popu-
lation with AF in Denmark, with the majority (72.0%)
of these 1,728 patients receiving hemodialysis.
Like many of the published cohorts, the majority of
these patients with CKD did not receive warfarin
treatment despite having higher stroke risk, probably
due to the concomitant higher bleeding risk. Of note,
fewer than one-fourth of these dialysis patients
(22.9%) were receiving warfarin. In contrast to this
study, another recently published study (3) suggested
otherwise—that warfarin use was not associated with
reduction in stroke risk but was associated with a
44.0% increase in bleeding events, resulting in an
absence of net clinical beneﬁt in patients with AF
undergoing dialysis. Despite such contrasting results
in these 2 large cohorts, the latter did not differen-
tiate between hemodialysis and peritoneal dialysis
patients, who might have differences in baseline
patient characteristics and stroke and bleeding risks.
One of the merits of the latter study was a higher
proportion (46.0%) of dialysis patients prescribed
warfarin. Although the net clinical beneﬁt of warfarin
is always a balance between stroke and bleeding
risk, our recent ﬁnding (4) using a hospital-based
cohort with 9,810 patients with AF with all patients
with end-stage CKD (2.76%) on peritoneal dialysis
showed a similar beneﬁt of warfarin as the Denmark
cohort. In particular, among 271 patients with end-
stage CKD, all received peritoneal dialysis, with 67
patients (24.6%) on warfarin, and no ischemic or
hemorrhagic stroke event was observed during a
mean follow-up of 3.19 years. Although the number of
patients with end-stage CKD was much smaller
compared with the aforementioned cohorts, warfarin
was demonstrated to achieve a net clinical beneﬁt of
stroke reduction. Of note, the mean CHA2DS2-VASc
and HAS-BLED scores from our cohort did not differ
from those of the 2 cohorts (2.97  2.01 and 2.56 
0.97, respectively). Whether peritoneal dialysis pa-
tients might beneﬁt differently from anticoagulation
is still debatable; in particular, the quality of anti-
coagulation, as reﬂected by the time in therapeutic
range, is largely unknown from most of these studies,
which might impact both the ischemic and hemor-
rhagic stroke risk.
Owing to the heterogeneous nature of patients
with end-stage CKD and the existing conﬂicting
results from the cohort studies, a large-scale ran-
domized controlled trial including hemodialysis and
peritoneal dialysis patients from different ethnic
origins might help to determine the optimal anti-
coagulation regimen in patients with end-stage CKD
on different modalities of renal replacement therapy.
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Dialysis Patients With Atrial FibrillationDrs. Chan and Siu reviewed the data on warfarin
for patients with atrial ﬁbrillation (AF) on dialysis.
They argued that one of the merits of the study
by Shah et al. (1) was the high prevalence of
warfarin users and that one of the merits of our
study was that we were able to distinguish between
patients on hemodialysis and patients on peritoneal
dialysis. Unfortunately, consensus on this important
subject has not yet been reached, and the prevalence
of warfarin usage among patients with AF and severe
chronic kidney disease varies among countries and
among clinics. In a recent Swedish study of patients
with post–myocardial infarction AF (2), only 66 of
478 patients (13.8%) with an estimated glomerular
ﬁltration rate of <16 ml/min/1.73 m2 received
warfarin at baseline compared with 46.0% of dialysis
patients in the study by Shah et al. (1).We agree that the net clinical beneﬁt of warfarin
may be different in patients with AF on peritoneal
dialysis than patients with AF on hemodialysis.
Most of the observational studies in this area have
focused on warfarin for hemodialysis patients (3,4),
and in our study, we only found a signiﬁcant effect
difference of warfarin between peritoneal and
hemodialysis patients among patients with low-risk
AF (a relatively small group) (5). Because we still
do not have data from randomized clinical trials
on the beneﬁt of warfarin in patients with AF on
dialysis, new data from observational cohorts are
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